Injectable Hydrogel Capable of In Situ Covalent Crosslinking for Permanent Embolization.

Publications // Shaoqin Gong // Dec 08 2021

PubMed ID: 34806359

Author(s): Xie R, Chen YC, Zhao Y, Yodsanit N, Wang Y, Yamamoto N, Yamanouchi D, Gong S. Injectable Hydrogel Capable of In Situ Covalent Crosslinking for Permanent Embolization. ACS Appl Mater Interfaces. 2021 Dec 8;13(48):56988-56999. doi: 10.1021/acsami.1c18250. Epub 2021 Nov 20. PMID 34806359

Journal: Acs Applied Materials & Interfaces, Volume 13, Issue 48, Dec 2021

Vascular embolization provides an effective approach for the treatment of hemorrhage, aneurysms, and other vascular abnormalities. However, current embolic materials, such as metallic coils and liquid embolic agents, are limited by their inability to provide safe, consistent, and controlled embolization. Here, we report an injectable hydrogel that can remain at the injection site and subsequently undergo in situ covalent crosslinking, leading to the formation of a dual-crosslinking network (DCN) hydrogel for endovascular embolization. The DCN hydrogel is simple to prepare, easy to deploy via needles and catheters, and mechanically stable at the target injection site, thereby avoiding embolization of nontarget vessels. It possesses efficient hemostatic activity and good biocompatibility. The DCN hydrogel is also clearly visible under X-ray imaging, thereby allowing for targeted embolization. In vivo tests in a rabbit artery model demonstrates that the DCN hydrogel is effective in achieving immediate embolization of the target artery with long-term occlusion by inducing luminal fibrosis. Collectively, the DCN hydrogel provides a viable, biocompatible, and cost-effective alternative to existing embolic materials with clinical translation potential for endovascular embolization.